Robey R - Search Results

1

Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines.

Blagosklonny MV, Dixon SC, Robey R, Figg WD. Blagosklonny MV, et al. Among authors: robey r. Int J Oncol. 2001 Apr;18(4):697-704. doi: 10.3892/ijo.18.4.697. Int J Oncol. 2001. PMID: 11251163

2

Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs.

Blagosklonny MV, Robey R, Bates S, Fojo T. Blagosklonny MV, et al. Among authors: robey r. J Clin Invest. 2000 Feb;105(4):533-9. doi: 10.1172/JCI8625. J Clin Invest. 2000. PMID: 10683383 Free PMC article.

3

Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells.

Blagosklonny MV, Bishop PC, Robey R, Fojo T, Bates SE. Blagosklonny MV, et al. Among authors: robey r. Cancer Res. 2000 Jul 1;60(13):3425-8. Cancer Res. 2000. PMID: 10910051

4

Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.

Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S. Chico I, et al. Among authors: robey r. J Clin Oncol. 2001 Feb 1;19(3):832-42. doi: 10.1200/JCO.2001.19.3.832. J Clin Oncol. 2001. PMID: 11157037 Clinical Trial.

5

Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.

Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Giannakakou P, et al. Among authors: robey r. Oncogene. 2001 Jun 28;20(29):3806-13. doi: 10.1038/sj.onc.1204487. Oncogene. 2001. PMID: 11439344

6

A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).

Bates S, Kang M, Meadows B, Bakke S, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg WD, Fojo T. Bates S, et al. Among authors: robey r. Cancer. 2001 Sep 15;92(6):1577-90. doi: 10.1002/1097-0142(20010915)92:6<1577::aid-cncr1484>3.0.co;2-h. Cancer. 2001. PMID: 11745237 Clinical Trial.

7

Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.

Bishop PC, Myers T, Robey R, Fry DW, Liu ET, Blagosklonny MV, Bates SE. Bishop PC, et al. Among authors: robey r. Oncogene. 2002 Jan 3;21(1):119-27. doi: 10.1038/sj.onc.1205028. Oncogene. 2002. PMID: 11791182

8

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. Sandor V, et al. Among authors: robey rw. Clin Cancer Res. 2002 Mar;8(3):718-28. Clin Cancer Res. 2002. PMID: 11895901 Clinical Trial.

9

Reversal of multidrug resistance: lessons from clinical oncology.

Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T. Bates SF, et al. Among authors: robey r. Novartis Found Symp. 2002;243:83-96; discussion 96-102, 180-5. Novartis Found Symp. 2002. PMID: 11990784 Review.

10

Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death.

Blagosklonny MV, Robey R, Sheikh MS, Fojo T. Blagosklonny MV, et al. Among authors: robey r. Cancer Biol Ther. 2002 Mar-Apr;1(2):113-7. doi: 10.4161/cbt.53. Cancer Biol Ther. 2002. PMID: 12170770 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

267 results

Search Page

Filters